Polyrizon Ltd. Ordinary Shares (PLRZ) - Net Assets
Based on the latest financial reports, Polyrizon Ltd. Ordinary Shares (PLRZ) has net assets worth $18.38 Million USD as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($18.74 Million) and total liabilities ($364.00K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check PLRZ financial resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $18.38 Million |
| % of Total Assets | 98.06% |
| Annual Growth Rate | 326.34% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Polyrizon Ltd. Ordinary Shares - Net Assets Trend (2020–2024)
This chart illustrates how Polyrizon Ltd. Ordinary Shares's net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of Polyrizon Ltd. Ordinary Shares for the complete picture of this company's asset base.
Annual Net Assets for Polyrizon Ltd. Ordinary Shares (2020–2024)
The table below shows the annual net assets of Polyrizon Ltd. Ordinary Shares from 2020 to 2024. For live valuation and market cap data, see PLRZ company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $5.29 Million | +2867.54% |
| 2023-12-31 | $-191.00K | +70.71% |
| 2022-12-31 | $-652.00K | -21633.33% |
| 2021-12-31 | $-3.00K | -118.75% |
| 2020-12-31 | $16.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Polyrizon Ltd. Ordinary Shares's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 363500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $10.35 Million | 195.84% |
| Total Equity | $5.29 Million | 100.00% |
Polyrizon Ltd. Ordinary Shares Competitors by Market Cap
The table below lists competitors of Polyrizon Ltd. Ordinary Shares ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Voyageur Pharmaceuticals Ltd
V:VM
|
$14.21 Million |
|
CAM Resources Bhd
KLSE:7128
|
$14.21 Million |
|
Omineca Mining and Metals Ltd
V:OMM
|
$14.22 Million |
|
Hampton Financial Corp
V:HFC
|
$14.22 Million |
|
Glen Burnie Bancorp
NASDAQ:GLBZ
|
$14.19 Million |
|
Grand Baoxin Auto Group Limited
F:6BA
|
$14.19 Million |
|
Vo2 Cap Holding AB
ST:VO2
|
$14.19 Million |
|
Klimator AB
ST:KLIMAT
|
$14.19 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Polyrizon Ltd. Ordinary Shares's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 57,000 to 5,286,000, a change of 5,229,000 (9173.7%).
- Net loss of 1,545,000 reduced equity.
- New share issuances of 3,674,000 increased equity.
- Other comprehensive income increased equity by 196,000.
- Other factors increased equity by 2,904,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-1.54 Million | -29.23% |
| Share Issuances | $3.67 Million | +69.5% |
| Other Comprehensive Income | $196.00K | +3.71% |
| Other Changes | $2.90 Million | +54.94% |
| Total Change | $- | 9173.68% |
Book Value vs Market Value Analysis
This analysis compares Polyrizon Ltd. Ordinary Shares's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.04x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 4194.44x to 0.04x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $0.00 | $16.00 | x |
| 2021-12-31 | $0.00 | $16.00 | x |
| 2022-12-31 | $-0.50 | $16.00 | x |
| 2023-12-31 | $0.03 | $16.00 | x |
| 2024-12-31 | $441.79 | $16.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Polyrizon Ltd. Ordinary Shares utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -29.23%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.05x
- Recent ROE (-29.23%) is above the historical average (-307.62%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -456.25% | 0.00% | 0.00x | 1.50x | $-74.60K |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-710.70K |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-713.80K |
| 2023 | -1052.63% | 0.00% | 0.00x | 9.81x | $-605.70K |
| 2024 | -29.23% | 0.00% | 0.00x | 1.05x | $-2.07 Million |
Industry Comparison
This section compares Polyrizon Ltd. Ordinary Shares's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Polyrizon Ltd. Ordinary Shares (PLRZ) | $18.38 Million | -456.25% | 0.02x | $14.20 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Polyrizon Ltd. Ordinary Shares
Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients. It also develops PL-14, a nas… Read more